Novel Methods and Pathways in Cancer Glycobiology Research

Novel Methods and Pathways in Cancer Glycobiology Research

1st Edition - February 1, 2023

Write a review

  • Editors: Charles Dimitroff, Karen Abbott
  • Hardcover ISBN: 9780323991773

Purchase options

Purchase options
Available for Pre-Order
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order

Description

Novel Methods and Pathways in Cancer Glycobiology Research, Volume 157 in the Advances in Cancer Research series, highlights new advances in the field, with this new volume presenting interesting chapters on a variety of topics, including The Clinical Role of Glycobiology on Ovarian Cancer Progression, The glycan biomarkers in the CA19-9 family: discoveries in biology and clinical applications, Innovative Methods to Discovery Biomarkers for Early Detection of Hepatocellular Cancer, Beyond Glyco-proteomics – Understanding the Role of Genetics in Cancer Biomarkers, Innovative Tools for O-Glycosite Profiling and Mucinomics in Cancer, Role of Tumor Cell Sialylation in Pancreatic Cancer Progression, and more. Other sections focus on The Impact of Galectin-3 and Its Ligands on Melanoma Progression, Role of O-GlcNAcylation on Cancer Stem Cells: Connecting Nutrient Sensing to Cell Plasticity, The Role of E-selectin Ligands in Leukemia Pathobiology, Heparan Sulfate Proteoglycans in Cancer: Pathogenesis and Therapeutic Potential, and Mapping the Tumor, Stroma and Immune N-Glycomes in Cancer Tissues.

Key Features

  • Provides the authority and expertise of leading contributors from an international board of authors
  • Presents the latest release in the Advances in Cancer Research series
  • Includes the latest information on the Novel Methods and Pathways in Cancer Glycobiology Research

Readership

This volume contains scientific findings/hypotheses that will educate cancer researchers on the historical and emerging roles of glycobiological factors serving as biomarkers of cancer development, as novel anti-cancer therapeutic targets, and/or as drivers of malignant transformation and disease progression.

Table of Contents

  • 1. The Clinical Role of Glycobiology on Ovarian Cancer Progression
    Karen Abbott
    2. The glycan biomarkers in the CA19-9 family: discoveries in biology and clinical applications
    Brian Haab and Randy Brand
    3. Innovative Methods to Discovery Biomarkers for Early Detection of Hepatocellular Cancer
    David M. Lubman and Yehia Mechref
    4. Beyond Glyco-proteomics – Understanding the Role of Genetics in Cancer Biomarkers
    Anand Mehta, Richard Drake,  Amit Singal, Yujin Hoshida
    5. Innovative Tools for O-Glycosite Profiling and Mucinomics in Cancer
    Sharon Pitteri, Carolyn Bertozzi, James Brooks
    6. Role of Tumor Cell Sialylation in Pancreatic Cancer Progression
    Susan L. Bellis and Lance Wells
    7. The Impact of Galectin-3 and Its Ligands on Melanoma Progression
    Charles Dimitroff and Stuart Haslam
    8. Role of O-GlcNAcylation on Cancer Stem Cells: Connecting Nutrient Sensing to Cell Plasticity
    Mauricio Reginato and Lauren Ball
    9. The Role of E-selectin Ligands in Leukemia Pathobiology
    Robert Sackstein
    10. Heparan Sulfate Proteoglycans in Cancer: Pathogenesis and Therapeutic Potential
    Lianchun Wang and Houjian Cai
    11. Mapping the Tumor, Stroma and Immune N-Glycomes in Cancer Tissues
    Richard Drake, Peggi Angel, Anand Mehta, Kiyoko Kinashita

Product details

  • No. of pages: 312
  • Language: English
  • Copyright: © Academic Press 2023
  • Published: February 1, 2023
  • Imprint: Academic Press
  • Hardcover ISBN: 9780323991773

About the Serial Volume Editors

Charles Dimitroff

Charles Dimitroff
Over the last 26 years, Dr. Dimitroff has established himself as leader in field of glycobiology and is highly motivated to translate his glycobiological findings to help cure diseases and improve the health of humans. His research focuses on understanding how sugars or ‘glycans’ regulate immune and cancer cell functions with the goal of developing new approaches to boost the immune system to fight diseases and to treat cancer progression. These efforts have led to a laboratory that operates one of the preeminent translational glycobiology programs in the US. Dr. Dimitroff spent his initial years as an independent PI at Brigham and Women’s Hospital (BWH)/Harvard Medical School (HMS) transitioning from Instructor to Associate Professor of Dermatology in the Department of Dermatology. He was a Faculty Member in the Harvard Immunology Ph.D. Program and was the Associate Director for Laboratory Research in BWH Dermatology. In 2019, he then joined the Herbert Wertheim College of Medicine (HWCOM) at Florida International University (FIU) as the Executive Associate Dean for Research and Professor (with Tenure) of Translational Medicine. He now has concentrated his administrative duties focusing as the Founding Director of the Translational Glycobiology Institute at FIU (TGIF), wherein he oversees translational glycoscience research. The TGIF is a one-of-kind institute with translational glycoscience investigators seeking cures for diseases and providing research opportunities for trainees at all academic levels with a special focus on underrepresented minorities and women in science. Dr. Dimitroff’s current translational glycobiology research is subdivided into (2) Programs: a Solid Cancer Research Program and an Immune Research Program. In the Solid Cancer Research Program, his research explores the glycome of metastatic melanomas and ascertains how the glycome drives melanoma metastasis and whether these glycobiological features can be used as biomarkers to predict melanoma metastasis. In the Immune Research Program, his research investigates how human B cell glycans control B cell fate and function. These investigations have unveiled new molecular insights on the regulation of a humoral immune response and vaccinations, and the treatment of B cell malignancies.

Affiliations and Expertise

Herbert Wertheim College of Medicine, Translational Glycobiology Institute, Department of Translational Medicine, Florida International University, FL, USA

Karen Abbott

Karen Abbott
Dr. Karen Abbott has been a leader in the field of glycoproteomics and biomarker discovery for over 14 years. Dr. Abbott received her PhD in Biochemistry at The University of Georgia in 2004. She was awarded an American Cancer Society Postdoctoral Fellowship in 2005 where she developed lectin capture methods for the analysis of glycoproteins from human tissues and plasma using mass spectrometry methods. She has been funded for ovarian cancer research by since 2010. She is currently funded by an Alliance of Glycobiologists NCI grant to understand how complex carbohydrates contribute to the development and progression of ovarian cancer. She is also currently funded by the NCI Innovative Molecular Analysis Technologies grant that supports the development of novel and transformative technologies to develop new therapeutics and diagnostics for cancer. Dr. Abbott joined the Herbert Wertheim College of Medicine (HWCOM) at Florida International University in 2020 as Associate Director for the Translational Glycobiology Institute. Her research is currently focused in three main areas: translational therapeutic development for ovarian cancer, studies on the role of Notch glycosylation in ovarian cancer progression, and technology development for the study of glycosylphosphatidylinositol anchored proteins.

Affiliations and Expertise

Associate Professor, Department of Translational Medicine, Herbert Wertheim College of Medicine (HWCOM), Florida International University (FIU), and Assistant Director, Translational Glycobiology Institute at FIU (TGIF), a center focused on collaborative translational research that fosters an environment that supports mentoring of the next generation of scientists and promotes research excellence.

Ratings and Reviews

Write a review

There are currently no reviews for "Novel Methods and Pathways in Cancer Glycobiology Research"